Related Experiment Videos
[Clinical study on lixin pill in treating congestive heart failure]
1Research Division of Cardiovascular Diseases, Xiyuan Hospital, China Academy of TCM, Beijing (100091).
Insights
Lixin Pill (LXP) combined with low-dose digoxin significantly improved congestive heart failure (CHF) outcomes. This combination therapy enhanced heart function and reduced arrhythmias more effectively than LXP or standard digoxin alone.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Congestive heart failure (CHF) remains a leading cause of morbidity and mortality worldwide.
- Effective therapeutic strategies for improving cardiac function and reducing complications in CHF patients are crucial.
Purpose of the Study:
- To evaluate the clinical efficacy of Lixin Pill (LXP) in treating patients diagnosed with congestive heart failure (CHF).
- To compare the therapeutic effects of LXP monotherapy, LXP combined with low-dose digoxin, and standard-dose digoxin in CHF management.
Main Methods:
- A randomized controlled trial involving 90 patients with CHF (NYHA heart function grade III-IV).
- Patients were allocated to three groups: LXP, LXP plus low-dose digoxin, or standard-dose digoxin.
- All groups received basic therapy including diuretics, nitrates, and ACE inhibitors for one month.
Main Results:
- The overall effective rates for improving heart function were 83.3% (LXP), 93.3% (LXP + low-dose digoxin), and 90.0% (standard digoxin).
- Lixin Pill combined with low-dose digoxin showed superior improvement in left ventricular ejection fraction (LVEF) compared to LXP alone (P < 0.05).
- Both LXP and the combination therapy significantly reduced supraventricular and ventricular premature contractions (P < 0.01 or P < 0.05), with the combination being more effective.
Conclusions:
- Lixin Pill (LXP) demonstrates therapeutic benefits in treating congestive heart failure.
- Combining LXP with a small dosage of digoxin enhances treatment efficacy for CHF patients.
- This combination therapy offers a promising approach for improving cardiac function and managing arrhythmias in CHF.
Objective:
To observe the clinical therapeutic effect of Lixin Pill (LXP) in treating patients with congestive heart failure (CHF).
Methods:
Ninety CHF patients with heart function of III-IV grade were randomly divided into 3 groups. Group A was treated with LXP, Group B with LXP plus small dosage of digoxin and Group C with ordinary dosage of digoxin. The therapeutic course for all the three groups was 1 month. Meanwhile, all patients were given ordinary dosage of diuretics, nitrates and angiotensin-converting enzyme inhibitors (ACEI) as basic therapy.
Results:
The total effective rate in improving heart function in Group A, B and C was 83.3%, 93.3% and 90.0% respectively. In respect of improving myocardial contraction and dilation, the left ventricular ejection fraction (LVEF) was improved in all the three groups but was more superior in Group B (P < 0.05); the ratio of maximum blood flow between the advanced and the early diastolic stage (A/E) was improved, and the complicated supraventricular and ventricular premature contraction in Group A and B were reduced markedly after treatment (P < 0.01 or P < 0.05), and the effect in Group B was superior to that in Group A.
Conclusion:
Using LXP combined with small dosage of digoxin could improve the therapeutic effect in treating patients suffering from congestive heart failure.